AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35979900
Drug: Original brand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original brand fidaxomicin (reference formulation)
Trial: 36398900
Drug: Morning intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning intake of antihypertensive medications
Trial: 36398900
Drug: Evening intake
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening intake of antihypertensive medications
Trial: 33947979
Drug: Topical loteprednol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical loteprednol etabonate (0.1%) and topical olopatadine (0.1%)
Trial: 33748058
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of biomarkers from stratum corneum (SC) samples for internal UV-dose.
Trial: 33748058
Drug: Personal UV-sensors
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal UV-sensors worn by workers to assess external UV-dose.
Trial: 32503662
Drug: Hydroxychloroquine sulphate
RxNorm normalized name: Hydroxychloroquine sulphate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulphate (400 mg twice daily for seven days)
Trial: 33781107
Drug: Ketamine (0.44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.44 mg/kg)
Trial: 33208099
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (30 mg/kg loading dose over 10 min, then 10 mg/kg per h until 10 min before end of surgery)
Trial: 33345840
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (fasting <90 mg/dL, 1 hour postprandial <120 mg/dL)
Trial: 33345840
Drug: Standard glycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glycemic control (fasting <95 mg/dL, 1 hour postprandial <140 mg/dL)
Trial: 35710213
Drug: Pilates program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates program twice a week for 10 weeks
Trial: 33474815
Drug: Oral synbiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral synbiotics supplement (1 sachet daily for 12 weeks)
Trial: 33474815
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 sachet daily for 12 weeks)
Trial: 35973827
Drug: MitoHeal® 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoHeal® 500 mg/day
Trial: 35973827
Drug: MitoHeal® 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoHeal® 1000 mg/day
Trial: 34913186
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg every 4 weeks
Trial: 34267550
Drug: galcanezumab 300
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: galcanezumab 300 mg
Trial: 33967202
Drug: Gemcitabine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine maintenance therapy after gemcitabine + platinum combination therapy
Trial: 33967202
Drug: Gemcitabine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine + platinum combination therapy
Trial: 34100024
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of SARS-CoV-2 antibodies
Trial: 35449818
Drug: Copaiba oil
RxNorm normalized name: COPAIBA OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copaiba oil (CPO) inhalation
Trial: 36465342
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose
Trial: 32160422
Drug: Olanzapine +
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine + 10 mg samidorphan tablets (OLZ/SAM)
Trial: 32160422
Drug: Olanzapine +
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine + placebo tablets (olanzapine)
Trial: 35546060
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention for nursing staff on appropriate medication therapy and guidance to recognize potentially harmful medications and adverse effects
Trial: 32956576
Drug: Delayed calcineurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed calcineurin inhibitor (CNI) substitution
Trial: 32067132
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=7), received care as usual (occupational therapy, music therapy, and exercise).
Trial: 38781013
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo or standard treatment)
Trial: 32608989
Drug: Integrated Approach
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Approach of Yoga Therapy (IAYT), 3 classes per week for 12 weeks
Trial: 32281466
Drug: Multisensory perceptual
RxNorm normalized name: TITANIUM DIOXIDE 17.6 mg in 1 mL / ZINC OXIDE 41.2 mg in 1 mL TOPICAL LOTION [Soleil Toujours Perpetual Radiance Broad Spectrum SPF 20]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory perceptual training with fluoxetine (20 mg daily)
Trial: 37414062
Drug: Sorafenib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib maintenance (400 mg orally twice daily)
Trial: 32588334
Drug: Dietary magnesium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary magnesium supplementation (2, 4, or 6 g/kg MgO)
Trial: 35672956
Drug: Sustained specialist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained specialist treatment (ST)
Trial: 35672956
Drug: Sustained specialist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained specialist treatment including Parent groups (ST + P)
Trial: 36482530
Drug: TLE 400
RxNorm normalized name: Stinging Nettle 400 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLE 400 (efavirenz 400 mg)
Trial: 36482530
Drug: TLE 600
RxNorm normalized name: PLEURAL DRAINAGE BOTTLE 600ML BRAUN #622272
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLE 600 (efavirenz 600 mg)
Trial: 32664948
Drug: Extended 6-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended 6-day course of artemether-lumefantrine and additional single low-dose primaquine (0.25 mg/kg) administered with the last dose.
Trial: 35658345
Drug: PKU‐ML model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKU‐ML model (machine learning diagnostic model)
Trial: 34347359
Drug: Prior metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior metformin use
Trial: 34347359
Drug: Long-term metformin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term metformin use
Trial: 32445077
Drug: Ketorolac (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (60 mg with 2% lignocaine)
Trial: 32445077
Drug: Methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40 mg with 2% lignocaine)
Trial: 35256446
Drug: Acetazolamide 750
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide 750 mg/day
Trial: 33594439
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) at 100% oxygen at 2.0 atmospheres per session, 5 days per week, for 8 weeks.
Trial: 33594439
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment arm (control group) receiving HBOT after a 12-week waiting period.
Trial: 32650814
Drug: OHI, 6-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OHI, 6-month use of powered tooth brushing, and 0.2% chlorhexidine gluconate mouth rinse (10 ml twice daily)
Trial: 34362422
Drug: Increasing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing treatment effect on the intermediate variable
Trial: 34362422
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of an interaction between treatment and confounder
Trial: 35061894
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg once daily)
Trial: 33974725
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder supplementation (1,600 mg/d for 3 months)
Trial: 33687748
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 100 U/mL (IDeg‐100)
Trial: 32529467
Drug: Gossypol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gossypol (20 mg once daily on days 1 to 14 every 21 days) combined with docetaxel (75 mg/m2) and cisplatin (75 mg/m2)
Trial: 32529467
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with docetaxel (75 mg/m2) and cisplatin (75 mg/m2)
Trial: 33080655
Drug: No anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anesthesia or pain medication
Trial: 33080655
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (sedation, local anesthesia, nonsteroidal antiinflammatory drugs)
Trial: 33736863
Drug: Denture cleaning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denture cleaning tablets
Trial: 33736863
Drug: Denture cleaning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denture cleaning tablets plus gingival cleaning tablets
Trial: 35144837
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) 1 g IV
Trial: 36099069
Drug: Saxagliptin +
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saxagliptin + Metformin (Saxa + Met)
Trial: 32716358
Drug: Polypharmacy (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (defined as taking five or more medications regularly)
Trial: 36708956
Drug: Vortioxetine 10-20
RxNorm normalized name: vortioxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10-20 mg/day
Trial: 34752723
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) gel pulpotomy
Trial: 34098993
Drug: Chokeberry juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chokeberry juice supplementation (200 ml per day for 7 weeks)
Trial: 33263744
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus 100 mg of aspirin once per day
Trial: 33263744
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of aspirin once per day
Trial: 33298013
Drug: Guideline concordant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline concordant Standard Care (gcSC) with adjunct exercise treatment for 12 weeks
Trial: 33298013
Drug: Adjunct exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct exercise treatment
Trial: 36011639
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment provided in Seremban health clinics
Trial: 35276716
Drug: Lurasidone 40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 40-80 mg/d
Trial: 35276716
Drug: Lurasidone 120-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 120-160 mg/d
Trial: 35961517
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of autologous skeletal muscle–derived cells
Trial: 35961517
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of autologous skeletal muscle–derived cells
Trial: 32447858
Drug: Nerve trunk
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve trunk stimulation therapy (Chize, Neiguan, Xiaohai)
Trial: 32440111
Drug: Nebulized glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glycopyrrolate (GLY) 25 µg twice daily (BID)
Trial: 34528132
Drug: 75 mL
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mL water (HYP)
Trial: 33892653
Drug: Dexamethasone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.1 mg/kg intravenous bolus 10 hours before surgery)
Trial: 34939580
Drug: Pentavac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavac vaccine
Trial: 34939580
Drug: Shan 5
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shan 5 vaccine
Trial: 34939580
Drug: Pentabio vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentabio vaccine
Trial: 33626198
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy & Exercises Group (MTEG)
Trial: 34563973
Drug: Oral Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ketamine
Trial: 36004709
Drug: HD +
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD + P. ostreatus (1 kg of P. ostreatus per week, four portions of 250 g)
Trial: 33945982
Drug: Thiamine 200
RxNorm normalized name: thiamine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine 200 mg IV three times daily for 7 days
Trial: 35016629
Drug: Conventional Occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Occupational Therapy (COT)
Trial: 36371623
Drug: Technology-based Comprehensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology-based Comprehensive Cardiac Rehabilitation Therapy (TaCT) electronic cardiac rehabilitation (eCR) intervention
Trial: 36324127
Drug: Twice-daily test
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily test mouth rinse containing Cetylpyridinium chloride (CPC) and essential oils for 12 weeks
Trial: 36123102
Drug: Highly absorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly absorbable oral curcumin (brand name: curcuRouge)
Trial: 38638400
Drug: Ranibizumab 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.1 mg
Trial: 33176727
Drug: Female treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Female treatment and concurrent male partner treatment (7 days of combined antibiotics - oral metronidazole 400 mg BID and 2% clindamycin cream applied topically to the glans penis and upper shaft BID)
Trial: 33176727
Drug: Current standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard of care (female treatment only)
Trial: 34154319
Drug: Aminoglycosides/colistin/combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycosides/colistin/combination
Trial: 32087836
Drug: MI-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI-based treatment engagement intervention (TE)
Trial: 34583841
Drug: Solution-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused therapy (SFT)
Trial: 34371978
Drug: All preload
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All preload treatments (IC and HC)
Trial: 32333168
Drug: Bright white
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white light therapy (BWLT) - 10,000 lx, active arm, twice-daily 1-hour sessions for 4 weeks
Trial: 32333168
Drug: Dim red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red light therapy (DRLT) - < 300 lx, control arm, twice-daily 1-hour sessions for 4 weeks
Trial: 33893842
Drug: Light-emitting diode
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-emitting diode therapy (LEDT)
Trial: 32574773
Drug: AKB-9778 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AKB-9778 treatment
Trial: 37061370
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (0.5 mL) HPV vaccine
Trial: 37061370
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (1.0 mL) HPV vaccine
Trial: 33435904
Drug: Rifampicin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (300 mg bd)
Trial: 33435904
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (up to 2000 mg daily)
Trial: 34086541
Drug: Risk factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factors including depressed mood, availability of illegal drugs, sensation-seeking behavior, social learning, peer's drug use
Trial: 33183504
Drug: Transcatheter bariatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter bariatric embolotherapy (TBE) targeting the left gastric artery using an occlusion balloon microcatheter to administer 300- to 500-μm embolic beads; patients also entered a lifestyle counseling program.
Trial: 33235284
Drug: Behavioral pharmacology
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral pharmacology (alcohol administration)
Trial: 33235284
Drug: Medications that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications that reduced stimulation, sedation, and craving during alcohol administration
Trial: 36100520
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of platelet-rich plasma
Trial: 33583066
Drug: Norepinephrine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (all doses)
Trial: 34099186
Drug: THC (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (15 mg, oral)
Trial: 33898959
Drug: Aldafermin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldafermin 0.3 mg
Trial: 35325622
Drug: Aldafermin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldafermin 1.0 mg
Trial: 35325622
Drug: Aldafermin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldafermin 3.0 mg
Trial: 32898998
Drug: Rational Emotive
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational Emotive Occupational Health Coaching (REOHC), 2-hour sessions weekly for 12 weeks
Trial: 35142814
Drug: Symptom monitoring
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom monitoring intervention (daily symptom reports displayed during oncology rounds)
Trial: 34413633
Drug: Oxycodone 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.25 mg/h (low-dose group)
Trial: 34413633
Drug: Oxycodone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.5 mg/h (control group)
Trial: 32141306
Drug: Galvanic current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galvanic current electrotherapy with conservative treatment (anti-inflammatory, vasodilatory and analgesic drugs) for 7 weeks, 3 times/week (20 sessions total)
Trial: 32141306
Drug: Galvanic current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galvanic current electrotherapy with conservative treatment
Trial: 32141306
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (anti-inflammatory, vasodilatory and analgesic drugs)
Trial: 36326824
Drug: High-dose convalescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose convalescent plasma (CCP)
Trial: 36326824
Drug: Higher cumulative
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher cumulative amount of neutralizing antibodies (subgroup of CCP)
Trial: 36319597
Drug: Daily calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily calorie restriction (Cal-R) (25% restriction daily)